Application of comparative genomics hybridization technique in determining genomic profiles and treatment in non-amplified mycn neuroblastoma patients in Vietnam
Main Article Content
Abstract
Neuroblastoma (NBL) is the most common extracranial solid cancer of childhood and is characterized by a remarkable biological heterogeneity, cause of mutiple genetic changes. The genetic profiles are the powerful tools for the clinical in risk stratification and choice of suitable treatment protocol in NBL patients. This will increase the chance of treatment’s success and minimize the chemotherapy per patient. Sample: 6 NBL patients lower 18 months, non-amplified MYCN in National Children’s Hospital. Method: The CGH technique is performed on the Agilent’s system with the 400k chip. Results: 4 patients are found the numerical chromosomal aberations (NCA) (both stage L2), the others are the segmental chromosomal aberations (SCA) (1 stage L2 and 1 stage M). Based on this results, 4/5 patients will stop the chemotherapy, 1 patient continues the treatment. The stage M patient has the 50% chance of success in high-dose chemotherapy and stem cell transplantation. Conclusion: The genomic profile by CGH is established successfully in Vietnam, bring to NBL patients the higher chance of complete treatment with the minimal chemotherapy.
References
2. Garnis C., Coe B. P., Lam S. L., MacAulay C. and Lam W. L. (2005), "High-resolution array CGH increases heterogeneity tolerance in the analysis of clinical samples", Genomics 85(6), 790-3.
3. Janoueix-Lerosey I., Schleiermacher G., Michels E., Mosseri V., Ribeiro A., Lequin D., Vermeulen J., Couturier J., Peuchmaur M., Valent A., Plantaz D., Rubie H., Valteau-Couanet D., Thomas C., Combaret V., Rousseau R., Eggert A., Michon J., Speleman F. and Delattre O. (2009), "Overall genomic pattern is a predictor of outcome in neuroblastoma", Journal of clinical oncology 27(7), 1026-33.
4. Kallioniemi A., Kallioniemi O. P., Sudar Da., Rutovitz D., Gray J. W., Waldman F. and Pinkel D. (1992), "Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors", Science 258, 818-821.
5. London W. B., Castleberry R. P., Matthay K. K., Look A. T., Seeger R. C., Shimada H., Thorner P., Brodeur G., Maris J. M., Reynolds C. P. and Cohn S. L. (2005), "Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group", Journal of clinical oncology 23(27), 6459-65.
6. Maris J. M. (2010), "Recent Advances in Neuroblastoma", The New England Journal of Medicine 362(23), 2202-2211.
7. Pinkel D. and Albertson D. G. (2005), "Array comparative genomic hybridization and its applications in cancer", Nature Genetics 37 Suppl, S11-7.
8. Thorner P. S. (2014), "The molecular genetic profile of neuroblastoma", Diagnostic Histopathology 20(2), 76-83.